Market Access News | pharmaphorum

News

CMS update on Alzheimer's coverage raises questions

The Centres for Medicare and Medicaid Services (CMS) has formally announced its intention to allow coverage of new amyloid-targeting drugs for Alzheimer’s disease if they

News

After FDA nod, Pfizer joins GSK in RSV vaccine market

The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to be cleared in th

News

Vydura is NHS’ first oral CGRP for migraine prevention

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this ye

News

Iovance eyes November FDA decision on melanoma cell therapy

Iovance Biotherapeutics could be a few months away from a first regulatory approval for lifileucel, which could be the first cell-based therapy for a solid tumour in the U

News

SGLT latecomer Lexicon gets heart failure okay

Lexicon Pharma tried and failed to get FDA approval for its SGLT inhibitor sotagliflozin for diabetes, but it has finally got the drug over the finish line – for a differe

News

EU approval for Novartis’ sickle cell drug set to be pulled

Novartis has said it is “disappointed” that the EMA’s Human Medicines Committee has recommended revoking the conditional EU approval for sickle cell disease (SCD) therapy

CMS update on Alzheimer's coverage raises questions

After FDA nod, Pfizer joins GSK in RSV vaccine market

Vydura is NHS’ first oral CGRP for migraine prevention

Iovance eyes November FDA decision on melanoma cell therapy

SGLT latecomer Lexicon gets heart failure okay

EU approval for Novartis’ sickle cell drug set to be pulled

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks